Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Delirium, Cognition Disorders
Interventions: Ziprasidone, Haloperidol, Placebo; Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 5
States / cities: Iowa City, Iowa • Chapel Hill, North Carolina • Greensboro, North Carolina + 1 more

Conditions: Overweight, Hyperlipidemia, Cardiovascular Diseases
Interventions: Aripiprazole; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Schizophrenia
Interventions: NaBen®, Placebo; Drug
Lead sponsor: SyneuRx International (Taiwan) Corp; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 20
States / cities: Dothan, Alabama • Bellflower, California • Long Beach, California + 17 more

Conditions: Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 68 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bipolar Disorder, Schizophrenia
Interventions: Not listed
Lead sponsor: Jess G. Fiedorowicz; Other
Eligibility: 18 Years to 50 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Diabetes, Obesity, Weight Gain
Interventions: Lifestyle Balance; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Long Beach, California • Sepulveda, California • West Los Angeles, California

Conditions: Posttraumatic Stress Disorder
Interventions: Adjunctive asenapine; Drug
Lead sponsor: Lori Davis, MD; Other
Eligibility: 19 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Conditions: Schizophrenia
Interventions: memantine HCl; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 13
States / cities: National City, California • San Diego, California • Miami, Florida + 10 more

Conditions: Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania
Interventions: Allopurinol, Placebo; Drug · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prodromal Schizophrenia, Psychotic Disorders
Interventions: risperidone, sertraline-primary; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 12 Years to 22 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Schizophrenia
Interventions: BI 409306, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 32
States / cities: Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 27 more

Conditions: Treatment-resistant Schizophrenia
Interventions: Evenamide 15 mg bid, Placebo; Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more

Conditions: Autism Spectrum Disorder
Interventions: Healthy Habits for Life; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 8 Years to 26 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Autism
Interventions: Aripiprazole; Drug
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 12 Years to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tardive Dyskinesia
Interventions: Not listed
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 34
States / cities: Little Rock, Arkansas • Anaheim, California • Long Beach, California + 29 more

Conditions: Fibromyalgia, Mitochondrial Diseases, Movement Disorders, Diabetes Mellitus, Type 2
Interventions: Metformin; Drug
Lead sponsor: Woodinville Psychiatric Associates; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Woodinville, Washington

Conditions: Psychosis
Interventions: Patients with psychosis will be treated with known antipsychotic medication; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 17 Years to 35 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Emergency Psychiatric, Cognition Disorder, Movement Disorders, Antipsychotics and Neuroleptics Toxicity, Dementia With Lewy Bodies, Alteration in Mental Status, Behavior, Aging
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 54 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Schizophrenia, Bipolar Disorder
Interventions: SULT4A1-1 genetic test; Genetic
Lead sponsor: Medco Health Solutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Franklin Lakes, New Jersey

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
Interventions: genetic analysis, genetic assay; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: ziprasidone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 28
States / cities: Phoenix, Arizona • Costa Mesa, California • Garden Grove, California + 23 more

Conditions: Autism Spectrum Disorder
Interventions: GWP42003-P, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Schizophrenia
Interventions: Drug: EVP-6308, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Dyskinesia, Drug-Induced
Interventions: Quetiapine, Risperidone, Olanzapine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

The MIND Study: Modifying the INcidence of Delirium

The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia

Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

Antipsychotics and Blood Vessel Function

Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2

An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder

Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients

Allopurinol Add-on Treatment for Refractory Mania

Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

Weight Management Intervention for Youth and Young Adults With Autism Spectrum Disorder

Aripiprazole in Children With Autism: A Pilot Study

Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Heart Rate Variability in Response to Metformin Challenge

Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study

DIAMOND-Lewy Guidelines for Antipsychotic Use in Older Patients

Relative Effectiveness of Schizophrenia Therapy Study

Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors

Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

Movement Disorders Caused by Antipsychotic Drugs in Older Patients